Track CARGO Therapeutics, Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

CARGO Therapeutics, Inc. Common Stock CRGX · Stock Open CARGO Therapeutics, Inc. Common Stock in new tab

4.47 USD
EPS
-4.62
P/B
0.87
ROE
-65.83
Loading chart...
Key Metrics
EPS-4.62
Book Value5.11
Price to Book0.87
Debt/Equity0.24
% Insiders0.629%
Estimates
Forward P/E-1.26
Forward EPS-4.66

DCF valuation

Model fair value for CARGO Therapeutics, Inc. Common Stock (CRGX)
Result
Sign in to run the valuation for CRGX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

CARGO Therapeutics, Inc. Common Stock Logo CARGO Therapeutics, Inc. Common Stock Analysis (CRGX)

Is CARGO Therapeutics, Inc. Common Stock a good investment? CARGO Therapeutics, Inc. Common Stock (CRGX) is currently trading at 4.47 USD.

Investor FAQ

Does CARGO Therapeutics, Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is CARGO Therapeutics, Inc. Common Stock?

CARGO Therapeutics, Inc. Common Stock is classified as a Stock.

Company Profile

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, focused on designing, engineering, and developing potentially curative cell therapies for cancer patients in the United States. The company develops CRG-023, a tri-specific CAR T product candidate which is in phase 1 that targets tumor cells with three B-cell malignancies; and allogeneic platform, a universal vector solution designed to effectively limit immune-based rejection to enable durable response of CAR T-cell therapy. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is based in San Carlos, California. As of August 18, 2025, CARGO Therapeutics, Inc. operates as a subsidiary of Concentra Biosciences, LLC.

Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion